August 7, 2023 07:31 AM EDTUpdated 09:26 AM
R&D

Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Amber Tong

Nek­tar Ther­a­peu­tics said its for­mer part­ner Eli Lil­ly had pre­sent­ed “er­ro­neous da­ta” for its atopic der­mati­tis drug be­fore break­ing off a $400 mil­lion al­liance. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times